Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products in…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
Orexo AB (ORXOY) Q2 2026 Earnings Call Highlights: Strategic Advances Amidst Legal and ... Orexo AB (ORXOY) showcases R&D progress and strategic collaborations while navigating legal hurdles and financial restructuring. | ||
Orexo AB (ORXOF) Q1 2026 Earnings Call Highlights: Strategic Divestment and R&D Investments ... Orexo AB (ORXOF) navigates a transitional quarter with a focus on restructuring, R&D advancements, and ongoing legal hurdles. | ||
Orexo AB (ORXOF) Q4 2025 Earnings Call Highlights: Strategic Divestment and Financial Resilience Orexo AB (ORXOF) strengthens its financial position with the successful sale of ZUBSOLV US business, while focusing on future growth through its AmorphOX technology platform. | ||
 Orexo (OM:ORX) Remains Unprofitable as Losses Persist Despite 5.6% Revenue Growth Outlook Orexo (OM:ORX) remains in the red, with losses having increased by an average of 3.1% per year over the past five years. There is no sign that profitability will emerge within the next three years. Operating and net profit margins show no improvement, and earnings growth remains elusive. On the bright side, revenue is forecast to grow at 5.6% per year, outpacing the broader Swedish market's expected rate of 3.6%. This positions the company for potential top-line momentum despite lingering... | ||